Alle Studien
AutorisiertTherapeutische Bestätigung (Phase III)Interventionell

Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

People receiving treatment for lymphoma often take high doses of steroid medicines as part of their chemotherapy. While these medicines are vital for treating cancer, they can rapidly weaken bones, leading to a condition called osteoporosis that makes bones more fragile and prone to breaking. This Phase 3 clinical trial is investigating whether a medicine called zoledronic acid can protect bones during cancer care. Zoledronic acid is already used to treat weak bones. Researchers want to see if giving it preventatively stops broken bones, particularly in the spine and hips, over a two-year period. Participants will have their bone density tracked using painless DXA scans at the start of the study and after two years. The results will help doctors understand if this medicine should become standard care to keep bones strong during lymphoma therapy.

Auf einen Blick

Status
Autorisiert
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Region Nordjylland
Einschreibeziel
132
Starten
07 Sep 2026

Worum geht es in dieser Studie?

Lymphoma is a type of blood cancer. Treatment often involves chemotherapy combined with powerful steroid drugs known as glucocorticoids. While these steroids are very effective at fighting cancer cells, they carry a common side effect: they cause bones to lose minerals quickly. This steroid-induced bone thinning can lead to osteoporosis, significantly raising the chance of painful fractures in the spine, hips, and other bones.

Zoledronic acid is a well-known bone-protecting drug that belongs to a group of medicines called bisphosphonates. It works by slowing down the natural process of bone breakdown, helping bones stay dense and strong. Doctors in this study want to see if giving zoledronic acid at the start of cancer treatment can act as a shield to stop bone loss before fractures happen.

Over the course of two years, researchers will monitor participants to see how many people suffer any broken bones. They will also use specialised low-dose X-ray scans (called DXA scans) to measure bone thickness in the lower spine and hip. The findings could change how cancer doctors protect their patients' long-term bone health across the UK and beyond.

Wichtige Erkenntnisse

  • Tests whether zoledronic acid prevents bone thinning caused by steroid chemotherapy.
  • Aimed at adults aged 18 and over who are being treated for lymphoma.
  • Involves an intravenous drip and painless DXA bone scans at the start and after two years.
  • Lasts for two years and runs alongside your regular cancer clinic appointments.
  • Participation is voluntary and does not replace your routine cancer care.

Wer könnte berechtigt sein?

This trial is open to adults aged 18 and over who have been diagnosed with lymphoma and are due to start chemotherapy that contains steroid medicines.

Both men and women can join. Because the study measures bone health over time, participants should be able to commit to follow-up visits and scans over a two-year period alongside their cancer appointments.

Certain people may not be able to take part—for example, those with severe kidney problems, very low calcium levels, or those already taking specific bone medications. Your doctor will review your medical history and routine blood tests to confirm if you are eligible.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged 18 or over.
  2. I have been diagnosed with lymphoma.
  3. I am about to start chemotherapy that includes steroid medicines.
  4. I am able to attend hospital check-ups and scans over a two-year period.
  5. I do not have severe kidney problems or uncontrolled low calcium levels.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you take part, your participation will last for two years. At the start, you will receive zoledronic acid, which is given as a slow drip into a vein (an intravenous infusion) that usually takes about 15 to 30 minutes. You will also have a painless bone density scan called a DXA scan to check your starting bone health. Over the two-year period, study visits will generally line up with your standard lymphoma hospital appointments. At the end of the two years, you will have a repeat DXA scan and imaging of your spine to check for any bone thinning or fractures.

Potenzielle Risiken und Vorteile

The possible benefit of joining is that zoledronic acid may strengthen your bones and protect you from painful fractures caused by steroid treatment. However, all medicines carry potential risks. The most common side effects of zoledronic acid are short-term, flu-like symptoms such as mild fever, headache, and aching muscles or joints for a couple of days after the drip. Less commonly, it can affect kidney function or calcium levels, and rarely it can cause jaw healing problems. You will be closely monitored with blood tests. Taking part is entirely voluntary, and you can withdraw at any time without it affecting your cancer treatment or NHS care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Dänemark

Häufige Fragen

What is zoledronic acid?

It is an established medicine that slows down bone loss, helping to keep bones dense, strong, and less likely to break.

Wie wird das Medikament verabreicht?

It is given as a drip into a vein (an intravenous infusion), usually taking around 15 minutes.

What is a DXA scan?

A DXA scan is a quick, painless, low-dose X-ray that measures the strength and thickness of your bones, typically at your hip and spine.

Will taking part interfere with my cancer treatment?

No. The study is designed to run alongside your planned chemotherapy, and your cancer team will coordinate your appointments.

Was passiert, wenn ich meine Meinung ändere?

You can leave the study at any point without giving a reason. Your standard medical care and relationship with your doctors will not be affected.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.